<DOC>
	<DOCNO>NCT02072070</DOCNO>
	<brief_summary>The purpose study determine whether TissueGene-C , allogeneic human chondrocytes express Transforming Growth Factor ( TGF ) -b1 , effective safe patient degenerative arthritis .</brief_summary>
	<brief_title>Efficacy Safety Study TissueGene-C Degenerative Arthritis</brief_title>
	<detailed_description>TissueGene-C biological new drug consist normal chondrocyte cell transduce chondrocyte cell express growth factor modify osteoarthritis symptom long term period . During Phase 3 clinical trial , compare TissueGene-C placebo 26 , 52 week trial 156 outpatient osteoarthritis . The outpatient randomize TissueGene-C placebo 1:1 ratio , monitor record term alleviate symptom , sport activity , function knee , presence adverse event .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>1 . Male female patient least 19 year age 2 . Patients diagnose degenerative arthritis 3 . Patients IKDC ( Knee Documentation Committee subjective score ) score 60 4 . Patients 100 mm VAS ( Visual Analog Scale ) score 40 5 . With Grade 3 osteoarthritis determine radiographic criterion Kellgren Lawrence 6 . With International Cartilage Repair Society ( ICRS ) Grade III IV cartilage damage major lesion , confirm MRI scan 7 . With Body Mass Index ( BMI ) high than18.5 lower 30 8 . Patients satisfy clinical/radiational criterion American College Rheumatology ( ACR ) guideline , apply one following . Older 50 Morning stiffness le 30 minute Crepitus Osteophytes 9 . With major lesion concentrate one section knee , major lesion consider main cause clinical symptom 10 . With alleviation symptom even least three month nonsurgical treatment 11 . Healthy , major finding physical examination , hematology , serum chemistry , urine test , significant medical history 12 . Agreed use effective contraceptive method study period 13 . Voluntarily agree participate study , sign informed consent form 1 . Showed clinically significant hematology , serum chemistry , urine test result screen visit 2 . Regarding inclusion criterion 6. follow patient include patient major lesion ICRS grade 4 large 6cm2 ( patient ICRS grade 4 ) patient major lesion ICRS grade 3 large 6cm2 ( patient without ICRS grade 4 ) , 3 . Patient skin disease around target knee 4. patient positive skin reaction CS10 5 . Patients administer drug oriental medicine , glucosamine chondroitin within 14 day baseline visit 6 . Patients take steroidal antiinflammatory medication within 14 day baseline visit 7 . Patients severe pain area could effect diagnosis symptoms 8 . History surgery like arthroendoscopy within past 6 month target knee 9 . Patients administer immunosuppressant , include antirheumatic drug ( include methotrexate antimetabolite ) , within past 3 month 10 . Patients treat physical therapy herbal remedy ( acupuncture , heat etc . ) within 2 week baseline visit 11 . History injection within past 3 month target knee 12 . Pregnant breastfeed female 13 . With another joint disease apart degenerative arthritis ( e.g. , systemic rheumatic inflammatory disease associate knee chondrocalcinosis , hemachromatosis , inflammatory arthritis , necrosis trochanter , Paget 's disease adjacent joint femur tibia , ochronosis , hemophilic arthropathy , infectious arthritis , Charcot 's disease knee joint , villonodular synovitis , synovial chondroma ) 14 . With infectious disease , include HIV hepatitis 15 . With follow clinically significant disease : heart disease ( e.g. , myocardial infarction , arrhythmia , serious heart disease , coronary artery bypass graft ) kidney disease ( e.g. , chronic renal failure , glomerulonephritis ) liver disease ( e.g. , liver cirrhosis , fatty liver , acute chronic liver disease ) endocrine disease ( e.g. , hyperthyroidism , hypothyroidism , thyroiditis , diabetes insipidus , Cushing 's disease ) insulindependent diabetes mellitus medical history past current malignant tumor In particular , tumor TissueGeneC may aggravate screen use follow test : Leukemia ( White Blood Cell level hematology ) Osteochondroma , Chondromas , Chondroblastoma , Chondromyxoid fibroma , Chondrosarcoma ( Alkaline phosphatase level hematology ) 16 . Participated another clinical trial ( use investigational drug medical device ) within 30 day enrollment study 17 . Patients administer TissueGeneC past clinical trial 18 . Considered inappropriate investigator participation study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>chondrocyte cell , Osteoarthritis , gene therapy</keyword>
</DOC>